Ryoncil® Sales Jump 60% to $35.1M; Secures $125M Low-Cost Financing
Summary
Mesoblast announced a 60% increase in Ryoncil® sales to $35.1 million for the December quarter and secured a new $125 million low-cost financing facility, significantly strengthening its financial position and supporting future growth.
Key Events
-
Strong Ryoncil® Sales Growth
Gross revenue from Ryoncil® sales increased by 60% quarter-over-quarter to US$35.1 million for the December 2025 quarter.
-
New $125M Financing Facility
Mesoblast secured a new five-year, interest-only facility with its largest shareholder, featuring substantially lower costs, no early repayment fees, no exit fees, and no encumbrance on material assets or intellectual property.
-
Balance Sheet Strengthening
The new facility enabled the full repayment of a prior senior secured loan and partial repayment of a subordinated royalty facility, significantly improving the company's financial flexibility.
-
Adult SR-aGvHD Trial Planned
Ryoncil® will be evaluated in a pivotal trial for adults with steroid-refractory acute graft-versus-host disease (SR-aGvHD), a market approximately three times larger than the current pediatric indication.
Analysis
Mesoblast reported robust quarterly sales growth for its FDA-approved Ryoncil®, indicating strong commercial traction. Concurrently, the company secured a substantial $125 million financing facility with highly favorable terms, significantly strengthening its balance sheet and reducing its cost of capital. This dual positive development provides substantial financial flexibility for strategic partnerships and future label expansion initiatives, positioning the company for continued growth.
At the time of this filing, MESO was trading at $21.45 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.5B. The 52-week trading range was $9.61 to $21.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.